The Global Oligonucleotide Synthesis Market was valued at USD 2.8 billion in 2025 and is estimated to grow at a CAGR of 12.5% to reach USD 8.6 billion by 2035.
Market expansion is driven by the growing pipeline of oligonucleotide therapeutics, the rising adoption of synthetic oligonucleotides across research and clinical settings, and the increasing commercialization of precision medicine and gene-editing technologies. Oligonucleotide synthesis continues to be a critical enabling technology across the life sciences sector, supplying essential nucleic acid components for therapeutic development, molecular research, and synthetic biology initiatives. Ongoing investments in manufacturing capabilities by leading commercial synthesis providers, together with sustained demand from multiple end-use industries, are expected to reinforce long-term market growth. Furthermore, the expanding implementation of molecular diagnostic solutions and precision medicine approaches continues to strengthen demand for synthetic oligonucleotides, which remain indispensable components in a wide range of genomic and molecular analysis applications across healthcare and research settings.
The products and services segment accounts for 53% share and is forecast to grow at a CAGR of 12.05% between 2026 and 2035. This segment includes commercial synthesis solutions that deliver research-grade, analytical-grade, and GMP-grade oligonucleotides designed to meet customer-specific sequence lengths, purity specifications, and chemical modification requirements. Its leading market position reflects the indispensable role of synthesis services as the foundation for virtually every downstream application, supporting activities ranging from scientific research to advanced pharmaceutical development and commercial manufacturing.
The pharmaceutical and biotechnology companies segment held 55% share and is projected to register a CAGR of 12.65% throughout 2035. Their market leadership is supported by the increasing reliance on synthetic oligonucleotides across multiple stages of drug development, including target discovery, lead optimization, preclinical evaluation, clinical manufacturing, and commercial production. To strengthen supply reliability and ensure uninterrupted manufacturing capacity, many organizations are entering long-term partnerships with GMP-certified synthesis providers, highlighting the strategic importance of dependable production capabilities for advancing oligonucleotide-based drug development programs and maintaining regulatory and operational continuity.
North America Oligonucleotide Synthesis Market captured USD 955.9 million in 2025, supported by its well-established pharmaceutical and biotechnology ecosystem and extensive research infrastructure. The United States generates most of the regional revenue, benefiting from consistent federal research funding, a strong concentration of clinical-stage biotechnology companies, and the presence of several leading providers specializing in oligonucleotide synthesis technologies and manufacturing services.
Key companies operating in the global oligonucleotide synthesis market include Thermo Fisher Scientific, Integrated DNA Technologies, LGC Biosearch Technologies, Bioneer, Eurogentec, Azenta Life Sciences, Eurofins, Maravai LifeSciences, GenScript, Twist Bioscience, Merck, and Agilent. Companies operating in the oligonucleotide synthesis market are strengthening their market position by expanding manufacturing capacity, enhancing GMP-compliant production capabilities, and investing in advanced synthesis technologies that improve scalability, quality, and turnaround times. Many participants are broadening their product portfolios through the introduction of customized oligonucleotide solutions with diverse purity levels and chemical modifications to address evolving customer requirements. Strategic collaborations with pharmaceutical companies, biotechnology firms, and research organizations remain a key approach for securing long-term business opportunities and supporting drug development pipelines. Organizations are also focusing on geographic expansion by establishing new production facilities and strengthening regional distribution networks.
This product will be delivered within 2-4 business days.
Market expansion is driven by the growing pipeline of oligonucleotide therapeutics, the rising adoption of synthetic oligonucleotides across research and clinical settings, and the increasing commercialization of precision medicine and gene-editing technologies. Oligonucleotide synthesis continues to be a critical enabling technology across the life sciences sector, supplying essential nucleic acid components for therapeutic development, molecular research, and synthetic biology initiatives. Ongoing investments in manufacturing capabilities by leading commercial synthesis providers, together with sustained demand from multiple end-use industries, are expected to reinforce long-term market growth. Furthermore, the expanding implementation of molecular diagnostic solutions and precision medicine approaches continues to strengthen demand for synthetic oligonucleotides, which remain indispensable components in a wide range of genomic and molecular analysis applications across healthcare and research settings.
The products and services segment accounts for 53% share and is forecast to grow at a CAGR of 12.05% between 2026 and 2035. This segment includes commercial synthesis solutions that deliver research-grade, analytical-grade, and GMP-grade oligonucleotides designed to meet customer-specific sequence lengths, purity specifications, and chemical modification requirements. Its leading market position reflects the indispensable role of synthesis services as the foundation for virtually every downstream application, supporting activities ranging from scientific research to advanced pharmaceutical development and commercial manufacturing.
The pharmaceutical and biotechnology companies segment held 55% share and is projected to register a CAGR of 12.65% throughout 2035. Their market leadership is supported by the increasing reliance on synthetic oligonucleotides across multiple stages of drug development, including target discovery, lead optimization, preclinical evaluation, clinical manufacturing, and commercial production. To strengthen supply reliability and ensure uninterrupted manufacturing capacity, many organizations are entering long-term partnerships with GMP-certified synthesis providers, highlighting the strategic importance of dependable production capabilities for advancing oligonucleotide-based drug development programs and maintaining regulatory and operational continuity.
North America Oligonucleotide Synthesis Market captured USD 955.9 million in 2025, supported by its well-established pharmaceutical and biotechnology ecosystem and extensive research infrastructure. The United States generates most of the regional revenue, benefiting from consistent federal research funding, a strong concentration of clinical-stage biotechnology companies, and the presence of several leading providers specializing in oligonucleotide synthesis technologies and manufacturing services.
Key companies operating in the global oligonucleotide synthesis market include Thermo Fisher Scientific, Integrated DNA Technologies, LGC Biosearch Technologies, Bioneer, Eurogentec, Azenta Life Sciences, Eurofins, Maravai LifeSciences, GenScript, Twist Bioscience, Merck, and Agilent. Companies operating in the oligonucleotide synthesis market are strengthening their market position by expanding manufacturing capacity, enhancing GMP-compliant production capabilities, and investing in advanced synthesis technologies that improve scalability, quality, and turnaround times. Many participants are broadening their product portfolios through the introduction of customized oligonucleotide solutions with diverse purity levels and chemical modifications to address evolving customer requirements. Strategic collaborations with pharmaceutical companies, biotechnology firms, and research organizations remain a key approach for securing long-term business opportunities and supporting drug development pipelines. Organizations are also focusing on geographic expansion by establishing new production facilities and strengthening regional distribution networks.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Product Type, 2022-2035 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Application, 2022-2035 ($ Mn)
Chapter 7 Market Estimates and Forecast, by End Use, 2022-2035 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
Chapter 9 Company Profiles
Companies Mentioned
- Agilent Technologies
- Azenta Life Sciences
- Bioneer
- Eurofins
- Eurogentec
- GenScript
- Integrated DNA Technologies
- LGC Biosearch Technologies
- Maravai LifeSciences
- Merck
- Thermo Fisher Scientific
- Twist Bioscience
